LOINC_NUM
stringlengths 3
8
| COMPONENT
stringlengths 2
246
| PROPERTY
stringlengths 1
29
| TIME_ASPCT
stringlengths 1
15
| SYSTEM
stringlengths 1
106
| SCALE_TYP
stringclasses 10
values | METHOD_TYP
stringlengths 1
57
⌀ | CLASS
stringlengths 2
24
| CLASSTYPE
int64 1
4
| LONG_COMMON_NAME
stringlengths 3
254
| SHORTNAME
stringlengths 2
51
⌀ | EXTERNAL_COPYRIGHT_NOTICE
stringlengths 39
2.6k
⌀ | STATUS
stringclasses 4
values | VersionFirstReleased
stringlengths 1
7
| VersionLastChanged
stringlengths 1
5
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
95724-1
|
Glycine receptor Ab
|
PrThr
|
Pt
|
Ser/Plas
|
Ord
|
IF
|
SERO
| 1 |
Glycine receptor Ab [Presence] in Serum or Plasma by Immunofluorescence
|
GlyR Ab SerPl Ql IF
| null |
ACTIVE
|
2.69
|
2.69
|
95725-8
|
Glycine receptor Ab
|
PrThr
|
Pt
|
CSF
|
Ord
|
IF
|
SERO
| 1 |
Glycine receptor Ab [Presence] in Cerebral spinal fluid by Immunofluorescence
|
GlyR Ab CSF Ql IF
| null |
ACTIVE
|
2.69
|
2.69
|
95726-6
|
3-Hydroxy-3-Methylglutaryl-Coenzyme A reductase Ab
|
ACnc
|
Pt
|
Ser/Plas
|
Qn
|
IA
|
SERO
| 1 |
3-Hydroxy-3-Methylglutaryl-coenzyme A reductase Ab [Units/volume] in Serum or Plasma by Immunoassay
|
HMGCR Ab SerPl IA-aCnc
| null |
ACTIVE
|
2.69
|
2.69
|
95727-4
|
Name
|
Pn
|
Pt
|
^Contact
|
Nom
| null |
ADMIN
| 2 |
Contact Name
|
Contact Name
| null |
ACTIVE
|
2.69
|
2.69
|
95728-2
|
Address
|
Addr
|
Pt
|
^Contact
|
Nom
| null |
ADMIN
| 2 |
Contact Address
|
Contact Address
| null |
ACTIVE
|
2.69
|
2.69
|
9572-9
|
Parvovirus B19 DNA
|
PrThr
|
Pt
|
Ser
|
Ord
|
Probe.amp.tar
|
MICRO
| 1 |
Parvovirus B19 DNA [Presence] in Serum by NAA with probe detection
|
B19V DNA Ser Ql NAA+probe
| null |
ACTIVE
|
1.0i
|
2.73
|
95729-0
|
Relationship to decedent
|
Type
|
Pt
|
^Contact
|
Nom
| null |
ADMIN
| 2 |
Relationship to decedent Contact
|
Rel to decedent Contact
| null |
ACTIVE
|
2.69
|
2.69
|
95730-8
|
Surviving spouse name
|
Pn
|
Pt
|
^Patient
|
Nom
| null |
ADMIN
| 2 |
Surviving spouse name
|
Surviving spouse name
| null |
ACTIVE
|
2.69
|
2.69
|
95731-6
|
Maiden name
|
Pn
|
Pt
|
^Mother
|
Nom
| null |
ADMIN
| 2 |
Mother's Maiden name
|
Mother's Maiden name
| null |
ACTIVE
|
2.69
|
2.69
|
95732-4
|
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - admission performance
|
-
|
RptPeriod
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - admission performance during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.7
|
95733-2
|
IRF-PAI v3.0, LCDS v4.00 - Bladder and bowel - admission
|
-
|
RptPeriod
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAI v3.0, LCDS v4.00 - Bladder and bowel - admission during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95734-0
|
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Self-care - discharge performance
|
-
|
RptPeriod
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAIv3.0, MDS v1.17.1, 1.17.2 - Self-care - discharge performance during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.7
|
95735-7
|
Bladder continence
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Bladder continence during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95736-5
|
Bowel continence
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Bowel continence during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
9573-7
|
Respiratory syncytial virus Ab.IgG
|
Titr
|
Pt
|
Ser
|
Qn
|
IF
|
MICRO
| 1 |
Respiratory syncytial virus IgG Ab [Titer] in Serum by Immunofluorescence
|
RSV IgG Titr Ser IF
| null |
ACTIVE
|
1.0i
|
2.73
|
95737-3
|
Expression of ideas and wants
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Expression of ideas and wants during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95738-1
|
Does the patient use a wheelchair or scooter
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Does the patient use a wheelchair/scooter during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95739-9
|
Indicate the type of wheelchair or scooter used
|
Type
|
RptPeriod
|
^Patient
|
Nom
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Indicate the type of wheelchair/scooter used during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95740-7
|
Understanding verbal and non-verbal content
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Understanding verbal and non-verbal content during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95741-5
|
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - admission performance
|
-
|
RptPeriod
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - admission performance during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.7
|
95742-3
|
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - discharge performance
|
-
|
RptPeriod
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Mobility - discharge performance during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.7
|
95743-1
|
Memory &or recall ability
|
Find
|
RptPeriod
|
^Patient
|
Nom
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Memory/recall ability during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95744-9
|
Hearing.ability to hear
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Hearing.ability to hear during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
9574-5
|
Respiratory syncytial virus Ab.IgM
|
Titr
|
Pt
|
Ser
|
Qn
|
IF
|
MICRO
| 1 |
Respiratory syncytial virus IgM Ab [Titer] in Serum by Immunofluorescence
|
RSV IgM Titr Ser IF
| null |
ACTIVE
|
1.0i
|
2.73
|
95745-6
|
Vision.ability to see in adequate light
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CMS Assessment
|
SURVEY.CMS
| 4 |
Vision.ability to see in adequate light during assessment period [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.69
|
95746-4
|
Progress note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Progress note
|
Immunology Prog note
| null |
ACTIVE
|
2.69
|
2.73
|
95747-2
|
Referral note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Referral note
|
Immunology Referral note
| null |
ACTIVE
|
2.69
|
2.69
|
95748-0
|
Education note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Education note
|
Immunology Educ note
| null |
ACTIVE
|
2.69
|
2.69
|
95749-8
|
Initial evaluation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Initial evaluation note
|
Immunology Initial eval note
| null |
ACTIVE
|
2.69
|
2.69
|
95750-6
|
Procedure note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology procedure note
|
Immunology Procedure note
| null |
ACTIVE
|
2.69
|
2.69
|
95751-4
|
Flowsheet
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Flowsheet
|
Immunology Flowsheet
| null |
ACTIVE
|
2.69
|
2.69
|
9575-2
|
Rotavirus Ab
|
Titr
|
Pt
|
Ser
|
Qn
|
Comp fix
|
MICRO
| 1 |
Rotavirus Ab [Titer] in Serum by Complement fixation
|
RV Ab Titr Ser CF
| null |
DISCOURAGED
|
1.0i
|
2.7
|
95752-2
|
Plan of care note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Plan of care note
|
Immunology Plan of care note
| null |
ACTIVE
|
2.69
|
2.69
|
95753-0
|
Evaluation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Immunology
|
DOC.ONTOLOGY
| 2 |
Immunology Evaluation note
|
Immunology Eval note
| null |
ACTIVE
|
2.69
|
2.69
|
95754-8
|
Referral note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Referral note
|
Allergy Referral note
| null |
ACTIVE
|
2.69
|
2.69
|
95755-5
|
Initial evaluation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Initial evaluation note
|
Allergy Initial eval note
| null |
ACTIVE
|
2.69
|
2.69
|
95756-3
|
Procedure note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy procedure note
|
Allergy Procedure note
| null |
ACTIVE
|
2.69
|
2.69
|
95757-1
|
Progress note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Progress note
|
Allergy Prog note
| null |
ACTIVE
|
2.69
|
2.73
|
95758-9
|
Flowsheet
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Flowsheet
|
Allergy Flowsheet
| null |
ACTIVE
|
2.69
|
2.69
|
95759-7
|
Plan of care note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Plan of care note
|
Allergy Plan of care note
| null |
ACTIVE
|
2.69
|
2.69
|
9576-0
|
Rubella virus Ab
|
ACnc
|
Pt
|
CSF
|
Qn
|
IA
|
MICRO
| 1 |
Rubella virus Ab [Units/volume] in Cerebral spinal fluid by Immunoassay
|
RUBV Ab CSF IA-aCnc
| null |
ACTIVE
|
1.0i
|
2.69
|
95760-5
|
Education note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Education note
|
Allergy Educ note
| null |
ACTIVE
|
2.69
|
2.69
|
95761-3
|
Consultation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Consult note
|
Allergy Consult note
| null |
ACTIVE
|
2.69
|
2.69
|
95762-1
|
Diagnostic study note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Diagnostic study note
|
Allergy Diag study note
| null |
ACTIVE
|
2.69
|
2.69
|
95763-9
|
Evaluation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Allergy
|
DOC.ONTOLOGY
| 2 |
Allergy Evaluation note
|
Allergy Eval note
| null |
ACTIVE
|
2.69
|
2.69
|
95764-7
|
Candida auris DNA
|
PrThr
|
Pt
|
Urine
|
Ord
|
Non-probe.amp.tar
|
MICRO
| 1 |
Candida auris DNA [Presence] in Urine by NAA with non-probe detection
|
C auris DNA Ur Ql NAA+non-probe
| null |
ACTIVE
|
2.69
|
2.69
|
95765-4
|
Candida auris DNA
|
PrThr
|
Pt
|
XXX
|
Ord
|
Non-probe.amp.tar
|
MICRO
| 1 |
Candida auris DNA [Presence] in Specimen by NAA with non-probe detection
|
C auris DNA Spec Ql NAA+non-probe
| null |
ACTIVE
|
2.69
|
2.69
|
95766-2
|
Candida auris DNA
|
PrThr
|
Pt
|
Bld
|
Ord
|
Non-probe.amp.tar
|
MICRO
| 1 |
Candida auris DNA [Presence] in Blood by NAA with non-probe detection
|
C auris DNA Bld Ql NAA+non-probe
| null |
ACTIVE
|
2.69
|
2.69
|
95767-0
|
Cefiderocol
|
Susc
|
Pt
|
Isolate
|
OrdQn
|
Agar diffusion
|
ABXBACT
| 1 |
Cefiderocol [Susceptibility] by Disk diffusion (KB)
|
Cefiderocol Islt KB
| null |
ACTIVE
|
2.69
|
2.69
|
95768-8
|
Parathyrin.1-84
|
SCnc
|
Pt
|
Ser/Plas
|
Qn
|
IA
|
CHEM
| 1 |
Parathyrin.1-84 [Moles/volume] in Serum or Plasma by Immunoassay
|
Parathyrin.1-84 SerPl IA-sCnc
| null |
ACTIVE
|
2.69
|
2.71
|
95769-6
|
BMPR1A gene deletion+duplication & full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
BMPR1A gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
|
BMPR1A Del+Dup + Full Mut Anl Bld/T
| null |
ACTIVE
|
2.69
|
2.69
|
95770-4
|
GALT gene targeted mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
GALT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method
|
GALT gene Mut Anl Bld/T
| null |
ACTIVE
|
2.69
|
2.69
|
95771-2
|
GATA2 gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
GATA2 gene full mutation analysis in Blood or Tissue by Sequencing
|
GATA2 gene Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
95772-0
|
IDH1 gene & IDH2 gene targeted mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
IDH1 and IDH2 genes targeted mutation analysis in Blood or Tissue by Molecular genetics method
|
IDH1 + IDH2 Mut Anl Bld/T
| null |
ACTIVE
|
2.69
|
2.69
|
95773-8
|
ACADM gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
ACADM gene full mutation analysis in Blood or Tissue by Sequencing
|
ACADM gene Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
95774-6
|
MSH6 gene deletion+duplication & full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
MSH6 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method
|
MSH6 gene Del+Dup + Full Mut Anl Bld/T
| null |
ACTIVE
|
2.69
|
2.69
|
95775-3
|
HGSNAT gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
HGSNAT gene full mutation analysis in Blood or Tissue by Sequencing
|
HGSNAT Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
95776-1
|
GNS gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
GNS gene full mutation analysis in Blood or Tissue by Sequencing
|
GNS Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
95777-9
|
ACADS gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
ACADS gene full mutation analysis in Blood or Tissue by Sequencing
|
ACADS gene Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
9577-8
|
Saint Louis encephalitis virus Ab
|
Titr
|
Pt
|
CSF
|
Qn
|
IF
|
MICRO
| 1 |
Saint Louis encephalitis virus Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
|
SLEV Ab Titr CSF IF
| null |
ACTIVE
|
1.0i
|
2.7
|
95778-7
|
TERT gene promotor region targeted mutation analysis
|
Find
|
Pt
|
Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
TERT gene promotor region targeted mutation analysis in Tissue by Molecular genetics method
|
TERT promotor region Mut Anl Tiss
| null |
ACTIVE
|
2.69
|
2.69
|
95779-5
|
TFE3 gene rearrangements
|
Find
|
Pt
|
Tiss
|
Doc
|
FISH
|
MOLPATH
| 1 |
TFE3 gene rearrangements in Tissue by FISH
|
TFE3 rearrange Tiss FISH
| null |
ACTIVE
|
2.69
|
2.69
|
95780-3
|
TFEB gene rearrangements
|
Find
|
Pt
|
Tiss
|
Doc
|
FISH
|
MOLPATH
| 1 |
TFEB gene rearrangements in Tissue by FISH
|
TFEB rearrange Tiss FISH
| null |
ACTIVE
|
2.69
|
2.69
|
95781-1
|
ATP7B gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
ATP7B gene full mutation analysis in Blood or Tissue by Sequencing
|
ATP7B gene Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
95782-9
|
ABCD1 gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
ABCD1 gene full mutation analysis in Blood or Tissue by Sequencing
|
ABCD1 gene Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.69
|
95783-7
|
ETV6 gene rearrangements
|
Find
|
Pt
|
Bld/Bone mar
|
Doc
|
FISH
|
MOLPATH
| 1 |
ETV6 gene rearrangements in Blood or Marrow by FISH
|
ETV6 rearrange Bld/Mar FISH
| null |
ACTIVE
|
2.69
|
2.69
|
95784-5
|
FGFR2 gene rearrangements
|
Find
|
Pt
|
Tiss
|
Doc
|
FISH
|
MOLPATH
| 1 |
FGFR2 gene rearrangements in Tissue by FISH
|
FGFR2 rearrange Tiss FISH
| null |
ACTIVE
|
2.69
|
2.69
|
95785-2
|
FOXL2 gene targeted mutation analysis
|
Find
|
Pt
|
Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
FOXL2 gene targeted mutation analysis in Tissue by Molecular genetics method
|
FOXL2 Mut Anl Tiss
| null |
ACTIVE
|
2.69
|
2.69
|
9578-6
|
Saint Louis encephalitis virus Ab
|
Titr
|
Pt
|
Ser
|
Qn
|
IF
|
MICRO
| 1 |
Saint Louis encephalitis virus Ab [Titer] in Serum by Immunofluorescence
|
SLEV Ab Titr Ser IF
| null |
ACTIVE
|
1.0i
|
2.73
|
95786-0
|
Gene XXX mutation analysis limited to known familial mutations
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Molgen
|
MOLPATH
| 1 |
Gene XXX mutation analysis limited to known familial mutations in Blood or Tissue by Molecular genetics method
|
Gene XXX Fam Mut Anl Bld/T
| null |
ACTIVE
|
2.69
|
2.69
|
95787-8
|
Adrenal cortical carcinoma probability
|
Likelihood
|
Pt
|
^Patient
|
Qn
|
Based on clinical data
|
CLIN.RISK
| 2 |
Adrenal cortical carcinoma probability [Likelihood] based on clinical data
|
ACC Prob from clin data
| null |
ACTIVE
|
2.69
|
2.69
|
95788-6
|
Adrenal malignancy other than adrenal cortical carcinoma probability
|
Likelihood
|
Pt
|
^Patient
|
Qn
|
Based on clinical data
|
CLIN.RISK
| 2 |
Adrenal malignancy other than ACC probability [Likelihood] based on clinical data
|
Other adrenal malig Prob from clin data
| null |
ACTIVE
|
2.69
|
2.69
|
95789-4
|
Benign mass probability
|
Likelihood
|
Pt
|
^Patient
|
Qn
|
Based on clinical data
|
CLIN.RISK
| 2 |
Benign mass probability [Likelihood] based on clinical data
|
Benign mass Prob from clin data
| null |
ACTIVE
|
2.69
|
2.69
|
95790-2
|
Adrenal cortical carcinoma probability
|
Likelihood
|
Pt
|
^Patient
|
Qn
|
Based on clinical+lab data
|
CLIN.RISK
| 2 |
Adrenal cortical carcinoma probability [Likelihood] based on clinical and lab data
|
ACC Prob from clin+lab data
| null |
ACTIVE
|
2.69
|
2.69
|
95791-0
|
Adrenal malignancy other than adrenal cortical carcinoma probability
|
Likelihood
|
Pt
|
^Patient
|
Qn
|
Based on clinical+lab data
|
CLIN.RISK
| 2 |
Adrenal malignancy other than ACC probability [Likelihood] based on clinical and lab data
|
Other adrenal malig Prob clin+lab data
| null |
ACTIVE
|
2.69
|
2.69
|
95792-8
|
Benign mass probability
|
Likelihood
|
Pt
|
^Patient
|
Qn
|
Based on clinical+lab data
|
CLIN.RISK
| 2 |
Benign mass probability [Likelihood] based on clinical and lab data
|
Benign mass Prob from clin+lab data
| null |
ACTIVE
|
2.69
|
2.69
|
95793-6
|
Immunization priority tier
|
Type
|
Pt
|
^Patient
|
Nom
| null |
PUBLICHEALTH
| 2 |
Immunization priority tier
|
Immunization priority tier
| null |
ACTIVE
|
2.69
|
2.69
|
9579-4
|
Tetrahydrocorticosterone
|
MRat
|
24H
|
Urine
|
Qn
| null |
CHEM
| 1 |
Tetrahydrocorticosterone [Mass/time] in 24 hour Urine
|
THB 24h Ur-mRate
| null |
ACTIVE
|
1.0i
|
2.42
|
95794-4
|
Adrenal insufficiency emergency action plan
|
Find
|
Pt
|
{Setting}
|
Doc
|
{Role}
|
DOC.ONTOLOGY
| 2 |
Adrenal insufficiency emergency action plan
|
Adrenal insufficiency action plan
| null |
ACTIVE
|
2.69
|
2.69
|
95795-1
|
HBG1 gene & HBG2 gene full mutation analysis
|
Find
|
Pt
|
Bld/Tiss
|
Doc
|
Sequencing
|
MOLPATH
| 1 |
HBG1 and HBG2 genes full mutation analysis in Blood or Tissue by Sequencing
|
HBG1 + HBG2 Full Mut Anl Bld/T Seq
| null |
ACTIVE
|
2.69
|
2.73
|
95796-9
|
Opioids panel
|
-
|
Pt
|
Urine
|
-
|
Screen
|
PANEL.DRUG/TOX
| 1 |
Opioids panel - Urine by Screen method
|
Opioids Pnl Ur Scn
| null |
ACTIVE
|
2.69
|
2.69
|
95797-7
|
Norfentanyl
|
PrThr
|
Pt
|
Urine
|
Ord
|
Screen
|
DRUG/TOX
| 1 |
Norfentanyl [Presence] in Urine by Screen method
|
Norfentanyl Ur Ql Scn
| null |
ACTIVE
|
2.69
|
2.69
|
95798-5
|
Normeperidine
|
PrThr
|
Pt
|
Urine
|
Ord
|
Screen
|
DRUG/TOX
| 1 |
Normeperidine [Presence] in Urine by Screen method
|
Normeperidine Ur Ql Scn
| null |
ACTIVE
|
2.69
|
2.69
|
95799-3
|
O-nortramadol
|
PrThr
|
Pt
|
Urine
|
Ord
|
Screen
|
DRUG/TOX
| 1 |
O-nortramadol [Presence] in Urine by Screen method
|
O-nortramadol Ur Ql Scn
| null |
ACTIVE
|
2.69
|
2.69
|
95800-9
|
Immunoglobulin light chains.free panel
|
-
|
-
|
Urine
|
-
| null |
PANEL.CHEM
| 1 |
Immunoglobulin light chains.free panel - Urine
|
Immunoglobulin LC free Pnl Ur
| null |
ACTIVE
|
2.69
|
2.69
|
95801-7
|
Immunoglobulin light chains.free & immunofixation panel
|
-
|
-
|
Urine
|
-
| null |
PANEL.CHEM
| 1 |
Immunoglobulin light chains.free and IFE panel - Urine
|
Immunoglobulin LC free + IFE Pnl Ur
| null |
ACTIVE
|
2.69
|
2.69
|
9580-2
|
Thyroxine Ab
|
ACnc
|
Pt
|
Ser
|
Qn
| null |
SERO
| 1 |
Thyroxine (T4) Ab [Units/volume] in Serum
|
T4 Ab Ser-aCnc
| null |
ACTIVE
|
1.0i
|
2.73
|
95802-5
|
Progress note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Breastfeeding
|
DOC.ONTOLOGY
| 2 |
Breastfeeding Progress note
|
Breastfeeding Prog note
| null |
ACTIVE
|
2.69
|
2.73
|
95803-3
|
Note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Breastfeeding
|
DOC.ONTOLOGY
| 2 |
Breastfeeding Note
|
Breastfeeding Note
| null |
ACTIVE
|
2.69
|
2.69
|
95804-1
|
Note
|
Find
|
Pt
|
Telehealth
|
Doc
|
Breastfeeding
|
DOC.ONTOLOGY
| 2 |
Breastfeeding Telehealth Note
|
Breastfeeding Telehealth Note
| null |
ACTIVE
|
2.69
|
2.69
|
95805-8
|
Evaluation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Breastfeeding
|
DOC.ONTOLOGY
| 2 |
Breastfeeding Evaluation note
|
Breastfeeding Eval note
| null |
ACTIVE
|
2.69
|
2.69
|
95806-6
|
Consultation note
|
Find
|
Pt
|
{Setting}
|
Doc
|
Breastfeeding
|
DOC.ONTOLOGY
| 2 |
Breastfeeding Consult note
|
Breastfeeding Consult note
| null |
ACTIVE
|
2.69
|
2.69
|
95807-4
|
Chylomicrons
|
PrThr
|
Pt
|
Urine
|
Ord
| null |
CHEM
| 1 |
Chylomicrons [Presence] in Urine
|
Chylo Ur Ql
| null |
ACTIVE
|
2.69
|
2.69
|
95808-2
|
Cholesterol & triglyceride & chylomicrons panel
|
-
|
Pt
|
Urine
|
-
| null |
PANEL.CHEM
| 1 |
Cholesterol and triglyceride and chylomicrons panel - Urine
|
Cholest+triglyceride+chylomicrons Pnl Ur
| null |
ACTIVE
|
2.69
|
2.69
|
95809-0
|
Carbapenem resistance genes
|
PrThr
|
Pt
|
Isolate/Specimen
|
Ord
|
Molgen
|
ABXBACT
| 1 |
Carbapenem resistance genes [Presence] by Molecular method
|
CPR genes Islt/Spm Ql
| null |
ACTIVE
|
2.69
|
2.69
|
9581-0
|
Western equine encephalitis virus Ab
|
Titr
|
Pt
|
Ser
|
Qn
|
IF
|
MICRO
| 1 |
Western equine encephalitis virus Ab [Titer] in Serum by Immunofluorescence
|
WEEV Ab Titr Ser IF
| null |
ACTIVE
|
1.0i
|
2.73
|
95810-8
|
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - discharge
|
-
|
RptPeriod
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - discharge [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.7
|
95811-6
|
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - admission
|
-
|
-
|
^Patient
|
-
|
CMS Assessment
|
PANEL.SURVEY.CMS
| 4 |
IRF-PAI v3.0, MDS v1.17.1, 1.17.2 - Functional abilities and goals - admission [CMS Assessment]
| null | null |
ACTIVE
|
2.69
|
2.7
|
95812-4
|
Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CAM.CMS
|
SURVEY.CMS
| 4 |
Did the patient have difficulty focusing attention, for example, being easily distractible or having difficulty keeping track of what was being said during assessment period [CAM.CMS]
| null |
Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.
|
ACTIVE
|
2.69
|
2.69
|
95813-2
|
Is there evidence of an acute change in mental status from the patient's baseline
|
Find
|
RptPeriod
|
^Patient
|
Ord
|
CAM.CMS
|
SURVEY.CMS
| 4 |
Is there evidence of an acute change in mental status from the patient's baseline during assessment period [CAM.CMS]
| null |
Copyright © 2003 Sharon K. Inouye, M.D., MPH. Adapted from: Inouye SK, vanDyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: The Confusion Assessment Method. A new method for detection of delirium. Ann Intern Med. 1990; 113: 941-948. Confusion Assessment Method: Training Manual and Coding Guide. Used with permission.
|
ACTIVE
|
2.69
|
2.69
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.